Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 270,000 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 270,000 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $60.33, for a total value of $16,289,100.00. Following the completion of the sale, the chief executive officer owned 6,000 shares of the company’s stock, valued at $361,980. The trade was a 97.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Ian Mortimer also recently made the following trade(s):

• On Tuesday, March 10th, Ian Mortimer sold 11,269 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $60.11, for a total value of $677,379.59.
• On Friday, January 2nd, Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00.

Xenon Pharmaceuticals Trading Down 2.6%

Shares of XENE opened at $59.04 on Thursday. The business’s 50 day moving average is $43.23 and its 200 day moving average is $41.69. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $63.95. The company has a market capitalization of $4.91 billion, a PE ratio of -13.54 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter last year, the firm earned ($0.84) EPS. Equities research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Xenon Pharmaceuticals News Summary

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 efficacy readout — Xenon’s azetukalner met its goal in the focal-onset seizures study (X-TOLE2), and management plans an NDA filing in Q3 2026, materially derisking the lead program and supporting near-term commercial value. Zacks: Azetukalner Study
• Positive Sentiment: Major capital raise — Xenon priced an upsized offering to raise roughly $650M at $57.00/share (with an underwriter option to add shares), which substantially strengthens the balance sheet to fund Phase 3/commercial work and reduces near-term financing risk. GlobeNewswire: Offering
• Positive Sentiment: Analyst optimism and higher price targets — Several firms boosted targets and reiterated buys (Deutsche Bank to $90, HC Wainwright to $74, Wells Fargo to $68, Needham bullish), which can drive buying interest and momentum. Deutsche Bank PT HC Wainwright Note
• Neutral Sentiment: HC Wainwright updated multi-year EPS forecasts (improving FY2028–FY2030 but nudging FY2027 slightly worse); the revisions show evolving model assumptions tied to program timing and commercialization, but remain estimates that can change with trial/regulatory developments. HC Wainwright EPS Revision
• Negative Sentiment: Insider selling — CEO Ian Mortimer and other insiders disclosed large open-market sales (Mortimer sold ~270k shares and others sold several thousand), substantially reducing insider ownership and potentially signaling liquidity-taking or governance concerns for some investors. SEC Filing: Insider Sales
• Negative Sentiment: Dilution risk — while the $650M raise boosts runway, the sizable share issuance (and potential additional underwriter option) increases outstanding shares and may pressure near-term per-share metrics. GlobeNewswire: Offering

Institutional Investors Weigh In On Xenon Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Elevation Point Wealth Partners LLC bought a new position in shares of Xenon Pharmaceuticals during the 2nd quarter valued at approximately $32,000. Danske Bank A S bought a new stake in Xenon Pharmaceuticals in the third quarter worth $32,000. Blue Trust Inc. boosted its stake in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares during the period. Kestra Advisory Services LLC purchased a new position in Xenon Pharmaceuticals during the fourth quarter worth $33,000. Finally, Aster Capital Management DIFC Ltd bought a new position in Xenon Pharmaceuticals during the third quarter valued at $39,000. 95.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

XENE has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Jefferies Financial Group set a $100.00 target price on Xenon Pharmaceuticals in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Finally, Wolfe Research initiated coverage on shares of Xenon Pharmaceuticals in a research note on Monday, February 23rd. They set an “outperform” rating and a $60.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $71.94.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.